GNPX
Genprex, Inc.
1W: -6.5%
1M: +1.1%
3M: -19.0%
YTD: +5.0%
1Y: -89.8%
3Y: -99.9%
5Y: -100.0%
$1.88
-0.04 (-2.08%)
After Hours: $1.85 (-0.03, -1.60%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress3 trades
ETF Holdings—
Key Statistics
Market Cap$3.1M
52W Range1.71-55
Volume237,851
Avg Volume1,047,545
Beta-0.72
Dividend—
Analyst Ratings
Company Info
CEORyan Confer
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2018-03-29
Websitegenprex.com
3300 Bee Cave Road
Austin, TX 78746
US
Austin, TX 78746
US
877 774 4679
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Latest News
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Berger Mark Stanley | F-InKind | 7,168 | $2.00 | 2026-02-27 |
| Confer Ryan M. | F-InKind | 9,330 | $2.00 | 2026-02-27 |
| Moreno Toscano Jose | A-Award | 9,000 | — | 2025-12-22 |
| Berger Mark Stanley | A-Award | 28,500 | — | 2025-12-22 |
| Confer Ryan M. | A-Award | 45,000 | — | 2025-12-22 |